Capricor Therapeutics met with the FDA last week for a type A meeting, during which CEO Linda Marbán aimed to explain to the ...

Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics Second Quarter 2025 Conference Call. [Operator Instructions] This call is being recorded on Monday, August 11, 2025. I ...

First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the ...

Capricor Therapeutics (CAPR) announced that the first subjects have been dosed in a Phase 1 clinical trial evaluating its StealthX exosome-based ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive ...

Papzimeos is the first immunotherapy approved for recurrent respiratory papillomatosis, a rare lung disorder involving the ...

In a report released today, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Cingulate Inc, with a price target of $11.00. The company’s shares closed yesterday at $4.21. Take advantage ...

As the Trump administration works to implement a “most-favored nation” policy, Lilly said it’s “rebalancing” prices to “align ...